Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has shared an announcement.
On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc. appointed Christopher Cooper as interim Co-Chief Executive Officer to enhance its capital markets and business capabilities. Cooper, with over 27 years of experience in management and finance, will work alongside Dr. Anatoly Dritschilo, who continues as Co-CEO overseeing scientific and clinical trial activities. This strategic appointment is expected to bolster decision-making, support fundraising, and accelerate the achievement of key milestones, particularly in the ongoing Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy. The company aims to enhance the effectiveness of radiation therapy while minimizing its side effects, striving to increase cancer cure rates, prolong patient survival, and improve quality of life.
YTD Price Performance: -50.59%
Average Trading Volume: 110,302
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.07M
Learn more about SHPH stock on TipRanks’ Stock Analysis page.